Oral delivery of GLP-1 peptide using recombinant Lactobacillus gasseri for the treatment of type 2 diabetes mellitus.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Oral delivery of GLP-1 peptide using recombinant Lactobacillus gasseri for the treatment of type 2 diabetes mellitus.
- Published In:
- Microbiology spectrum, 13(8), e0282824 (2025)
- Authors:
- Ke, Zhiqiang, Ma, Qianqian, Ye, Xiaonan, Jin, Yan, Wang, Yanlin, Zhao, Xinyuan, Su, Zhengding
- Database ID:
- RPEP-11768
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-11768APA
Ke, Zhiqiang; Ma, Qianqian; Ye, Xiaonan; Jin, Yan; Wang, Yanlin; Zhao, Xinyuan; Su, Zhengding. (2025). Oral delivery of GLP-1 peptide using recombinant Lactobacillus gasseri for the treatment of type 2 diabetes mellitus.. Microbiology spectrum, 13(8), e0282824. https://doi.org/10.1128/spectrum.02828-24
MLA
Ke, Zhiqiang, et al. "Oral delivery of GLP-1 peptide using recombinant Lactobacillus gasseri for the treatment of type 2 diabetes mellitus.." Microbiology spectrum, 2025. https://doi.org/10.1128/spectrum.02828-24
RethinkPeptides
RethinkPeptides Research Database. "Oral delivery of GLP-1 peptide using recombinant Lactobacill..." RPEP-11768. Retrieved from https://rethinkpeptides.com/research/ke-2025-oral-delivery-of-glp1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.